Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Front Public Health ; 11: 1154813, 2023.
Article in English | MEDLINE | ID: mdl-37538275

ABSTRACT

Mainstays of opioid overdose prevention include medications for opioid use disorder (e.g., methadone or buprenorphine) and naloxone distribution. Inadequate access to buprenorphine limits its uptake, especially in communities of color, and people with opioid use disorders encounter multiple barriers to obtaining necessary medications including insurance, transportation, and consistent availability of telephones. UMass Memorial Medical Center and our community partners sought to alleviate these barriers to treatment through the deployment of a mobile addiction service, called the Road to Care. Using this approach, multidisciplinary and interprofessional providers deliver holistic addiction care by centering our patients' needs with respect to scheduling, location, and convenience. This program also extends access to buprenorphine and naloxone among people experiencing homelessness. Additional systemic and individualized barriers encountered are identified, as well as potential solutions for future mobile addiction service utilization. Over a two-year period, we have cared for 1,121 individuals who have accessed our mobile addiction service in over 4,567 encounters. We prescribed buprenorphine/naloxone (Suboxone®) to 330 individuals (29.4% of all patients). We have distributed nearly 250 naloxone kits directly on-site or and more than 300 kits via prescriptions to local pharmacies. To date, 74 naloxone rescue attempts have been reported back to us. We have demonstrated that a community-based mobile addiction service, anchored within a major medical center, can provide high-volume and high-quality overdose prevention services that facilitate engagement with additional treatment. Our experience is described as a case study below.


Subject(s)
Buprenorphine , Drug Overdose , Opioid-Related Disorders , Humans , Community Health Services , Naloxone/therapeutic use , Buprenorphine, Naloxone Drug Combination/therapeutic use , Opioid-Related Disorders/prevention & control , Opioid-Related Disorders/drug therapy , Buprenorphine/therapeutic use , Drug Overdose/drug therapy , Drug Overdose/prevention & control
2.
J Cell Physiol ; 200(1): 63-70, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15137058

ABSTRACT

Circadian rhythms exist for hematopoiesis, but little is known about circadian variation of bone marrow engraftability and host "acceptability". Using a B6.SJL to C57BL/6J congenic transplant model, we chose 3-times with light on: Hours After Light Onset (HALO) 4, 8, and 12 and 3-times with light off: HALO 16, 20, and 24. The mice were conditioned on a 12-h light/dark cycles. Recipient mice (100 cGy) received 40 million cells. We demonstrated a significant variation of bone marrow engraftability into bone marrow, spleen, and thymus when donor animals were subjected to changes in their light/dark cycles. Two statistically significant nadirs in all three organs were observed at HALO 8 and 24 in experiments carried out in July, while an identical set of experiments in February analyzing engraftment in marrow and spleen showed nadirs at HALO 8, but not at HALO 24. Marrow progenitors from the July experiments showed nadirs at HALO 12 and 24. The percentage of progenitors in S phase peaked at HALO 8 and 24. Interestingly, there were no changes in the ability of host to accept grafts with changes in the light/dark cycles of host animals. Circadian variations of bone marrow engraftability are important and should be considered in bone marrow transplant strategies.


Subject(s)
Bone Marrow Transplantation/methods , Circadian Rhythm , Genetic Variation , Animals , Bone Marrow Cells/cytology , Cell Count , Cell Lineage , Cells, Cultured , Colony-Forming Units Assay , Femur/cytology , Male , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Seasons , Spleen/cytology , Thymidine/metabolism , Thymus Gland/cytology , Tibia/cytology , Time Factors , Transplantation, Heterologous , Tritium
3.
Blood Cells Mol Dis ; 32(1): 47-51, 2004.
Article in English | MEDLINE | ID: mdl-14757412

ABSTRACT

The hematopoietic stem cell population, lineage negative-Sca positive (HSC), displays a homing defect into bone marrow (BM) after 48-h exposure to interleukin (IL)-3, IL-6, IL-11, and steel factor [J. Hematother. Stem Cell Res. 11 (2002) 913]. Cytokine treatment of murine marrow leads to reversible alterations in adhesion protein expression, which may explain the changes in homing. We evaluated 3 h homing to nonhematopoietic organs of marrow cells exposed to cytokines for 0, 18, 24, 40 and 48 h. HSC cells from C57BL/6J mice were cultured and labeled with the cytoplasmic fluorescent dye CFSE. We found homed events from uncultured cells in spleen, liver and lung, but no events were seen in duodenum or anterior tibialis muscle. Culture in cytokines led to decreased homing to marrow at 24 and 48 h with parallel changes in spleen homing. There was little variability of homing to liver, however the number, of homed events in lung was markedly increased when 24-h cultured cells were assessed. This was approximately a 10-fold increase compared to the 0 h time point (flow cytometry). Homing was determined by evaluation of frozen section (8 microm) by fluorescent microscopy for spleen, liver, duodenum, anterior tibialis and lung. Data were confirmed by flow cytometry from each organ including marrow. These data indicate the presence of a lung homing "hotspot" at 24 h of cytokine culture; this is a time when the stem progenitors cells are in mid S-phase. Altogether these data suggest that homing of marrow cell to nonmarrow organs may fluctuate with cell cycle transit and that there is a lung homing hotspot in mid-S.


Subject(s)
Cell Differentiation , Cell Movement , Stem Cells/cytology , Animals , Cell Cycle , Lung/cytology , Mice , Stem Cell Transplantation/methods , Stem Cells/physiology
4.
J Cell Physiol ; 197(2): 251-60, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14502565

ABSTRACT

Studies using chronic in vivo BrdU exposure, isolating primitive stem cells, and determining BrdU labeling, indicate that stem cells cycle. BrdU is also incorporated into DNA during damage/repair. DNA, which has incorporated BrdU due to cycle transit is heavier than normal, while the density of DNA with damage/repair incorporation is intermediate. DNA density of purified lineage-rhodamine low (rho(low)) Hoechst low (Ho(low)) stem cells or FDC-P1 cell line cells-was assessed in vitro, after exposure to cytokines and BrdU (cycling model) or cytokines and BrdU with bleomycin to induce strand breaks and hydroxyurea to halt cycle progression (damage/repair model). We determined DNA density using cesium chloride (CsCl) gradients and either fluorometry or dot blot chemiluminesence. DNA from BrdU labeled cycling Lin-rho(lo)Ho(lo) or FDC-P1 cells was heavier than normal DNA, while damage repair DNA had an intermediate density. We then assessed BrdU labeling of Lin-rho(lo)Ho(lo) cells in vivo. We found that 70.9% of lin-rho(lo)Ho(lo) cells labeled at 5 weeks. DNA density of these cells was low, in the damage/repair range, but similar results were obtained with stem cells, which had proliferated in vivo. Dilution of BrdU in in vitro culture of proliferating FDC-P1 cells also resulted in damage/repair density. We conclude that in vitro BrdU labeling models can distinguish between proliferation and damage/repair, but that we cannot obtain high enough in vivo levels to address this issue. All together, while we cannot absolutely exclude damage/repair as contributing to stem cell BrdU labeling, the data indicate that primitive bone marrow stem cells are probably a cycling population.


Subject(s)
Bromodeoxyuridine/metabolism , Cell Cycle/genetics , DNA Damage/genetics , DNA Repair/genetics , DNA/metabolism , Hematopoietic Stem Cells/metabolism , Animals , Bleomycin/pharmacology , Cell Cycle/drug effects , Cell Line , Cesium , Chlorides , Chromosomes/drug effects , Chromosomes/genetics , Cytokines/pharmacology , DNA/drug effects , DNA Damage/drug effects , DNA Repair/drug effects , Dose-Response Relationship, Drug , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/drug effects , Hydroxyurea/pharmacology , Mice , Photic Stimulation/adverse effects
5.
J Exp Med ; 197(11): 1563-72, 2003 Jun 02.
Article in English | MEDLINE | ID: mdl-12782718

ABSTRACT

We studied the genetic and engraftment phenotype of highly purified murine hematopoietic stem cells (lineage negative, rhodamine-low, Hoechst-low) through cytokine-stimulated cell cycle. Cells were cultured in interleukin (IL)-3, IL-6, IL-11, and steel factor for 0 to 48 h and tested for engraftment capacity in a lethally irradiated murine competitive transplant model. Engraftment showed major fluctuations with nadirs at 36 and 48 h of culture and recovery during the next G1. Gene expression of quiescent (0 h) or cycling (48 h) stem cells was compared with lineage positive cells by 3' end PCR differential display analysis. Individual PCR bands were quantified using a 0 to 9 scale and results were visually compared using color-coded matrices. We defined a set of 637 transcripts expressed in stem cells and not expressed in lineage positive cells. Gene expression analyzed at 0 and 48 h showed a major shift from "stem cell genes" being highly expressed at 0 h and turned off at 48 h, while "cell division" genes were turned on at 48 h. These observations suggest stem cell gene expression shifts through cell cycle in relation to cell cycle related alterations of stem cell phenotype. The engraftment defect is related to a major phenotypic change of the stem cell.


Subject(s)
Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/metabolism , Animals , Base Sequence , Cell Cycle , DNA, Complementary/genetics , Female , Gene Expression , Gene Expression Profiling , Hematopoietic Stem Cells/drug effects , Interleukin-11/pharmacology , Interleukin-3/pharmacology , Interleukin-6/pharmacology , Kinetics , Mice , Mice, Inbred BALB C , Phenotype , Stem Cell Factor/pharmacology
6.
J Neurosci Methods ; 117(2): 111-21, 2002 Jun 30.
Article in English | MEDLINE | ID: mdl-12100976

ABSTRACT

Epidermal growth factor (EGF) responsive neural progenitors are defined by clonal growth from single cells. In previous studies we were unable to obtain clones at single cell densities using trypsinized cells and trituration alone always gave cellular aggregates. Here we report on single cell derived clones using a technique involving trituration of EGF responsive neurospheres, cell filtration, and single cell sorting using a MoFlo high speed fluorescence activated cell sorter. Single cell deposition was confirmed by labeling cells with Hoechst 33342 and Flow-check Fluorospheres, and visualization by fluorescence microscopy. The cells were deposited into liquid medium and grown from single cells in 10-20 ng/ml EGF for 12-14 days. This gave a cloning efficiency of 2.12%+/-0.37. New colonies occurred as late as day 18 post-sort. Tritiated thymidine suicide indicates that a percentage of these cells are cycling. Immunohistochemical analysis for oligodendrocytes, astroglia, and neuronal lineages performed on colonies at 10-14 and 21-28 days gave 39% uni-lineage, 36% bi-lineage, and 25% tri-lineage colonies. A total of five different types of progenitor cells were observed. In individual colonies, oligodendrons predominated with a lesser presence of astroglial or neuronal cell types. This approach establishes a reliable and reproducible method for single cell cloning of neurosphere cells.


Subject(s)
Cell Separation/methods , Epidermal Growth Factor/pharmacology , Neurons/cytology , Stem Cells/cytology , Animals , Antimetabolites , Biomarkers , Bromodeoxyuridine , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Lineage , Cell Separation/instrumentation , Clone Cells , Immunohistochemistry , Mice , Mice, Inbred BALB C , Neurons/drug effects , Stem Cells/drug effects
7.
Exp Hematol ; 30(7): 792-800, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12135678

ABSTRACT

OBJECTIVE: Subsetting of Hoechst 33342 dull (Ho(dull)) hematopoietic stem cells on the basis of rhodamine 123 (Rh) efflux utilizing an improved dual-dye efflux strategy resolves Ho(dull)/Rh(dull) stem cell subsets that differ with regard to their rate of recruitment and progression through the cell cycle upon exposure to cytokines. MATERIALS AND METHODS: Murine bone marrow cells were isolated by negative immunomagnetic selection using lineage-directed antibodies followed by Ho and Rh staining using a dual-dye efflux method. RESULTS: Ho(dull)/Rh(dull) stem cells that efflux Rh more efficiently (R1) exhibit a 4- to 8-hour delay in progression to S phase when stimulated by interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor (SCF) compared to Ho(dull)/Rh(medium) stem cells, which retain low levels of Rh (R2). R1 and R2 cells show a hierarchical entry into S phase upon exposure to any or all of these cytokines. The R1 subset contains proportionately more high proliferative potential colony-forming cells than the R2 subset, but equivalent levels of engraftable stem cells at 3 and 8 weeks after competitive transplantation. Both R1 and R2 cells express c-kit, IL-3R, and IL-11R, whereas IL-6R and c-fms are only expressed by R1 or R2 cells, respectively. Cytokine stimulation of R1 and R2 cells induced cell cycle progression with elevated or induced expression of c-kit, c-fms, IL-2R, and IL-6R. CONCLUSION: These studies indicate that primitive marrow stem cells can be further subsetted by degree of Rh staining to reveal important functional phenotypic differences between cells with different levels of Rh staining.


Subject(s)
Benzimidazoles/analysis , Cytokines/pharmacology , Fluorescent Dyes/analysis , G1 Phase/physiology , Hematopoietic Stem Cells/classification , Receptors, Cytokine/drug effects , Rhodamine 123/analysis , S Phase/physiology , Animals , Benzimidazoles/metabolism , Biological Transport , Biomarkers , Bone Marrow Cells/classification , Bone Marrow Cells/cytology , Bone Marrow Cells/drug effects , Bone Marrow Cells/metabolism , Bone Marrow Transplantation , Cell Lineage , Colony-Forming Units Assay , Female , Fluorescent Dyes/metabolism , Graft Survival , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/drug effects , Hematopoietic Stem Cells/metabolism , Immunomagnetic Separation , Interleukin-11/pharmacology , Interleukin-11 Receptor alpha Subunit , Interleukin-3/pharmacology , Interleukin-6/pharmacology , Mice , Mice, Inbred BALB C , Proto-Oncogene Proteins c-kit/biosynthesis , Proto-Oncogene Proteins c-kit/genetics , Receptor, Macrophage Colony-Stimulating Factor/biosynthesis , Receptor, Macrophage Colony-Stimulating Factor/genetics , Receptors, Cytokine/biosynthesis , Receptors, Cytokine/genetics , Receptors, Interleukin/biosynthesis , Receptors, Interleukin/drug effects , Receptors, Interleukin/genetics , Receptors, Interleukin-11 , Receptors, Interleukin-2/biosynthesis , Receptors, Interleukin-2/genetics , Receptors, Interleukin-3/biosynthesis , Receptors, Interleukin-3/drug effects , Receptors, Interleukin-3/genetics , Receptors, Interleukin-6/biosynthesis , Receptors, Interleukin-6/drug effects , Receptors, Interleukin-6/genetics , Rhodamine 123/metabolism , Stem Cell Factor/pharmacology , Time Factors , Up-Regulation/drug effects
8.
Trans Am Clin Climatol Assoc ; 113: 182-206; discussion 206-7, 2002.
Article in English | MEDLINE | ID: mdl-12053709

ABSTRACT

Recent studies have indicated that bone marrow stem cells are capable of generating muscle, cardiac, hepatic, renal, and bone cells. Purified hematopoietic stem cells have generated cardiac and hepatic cells and reversed disease manifestations in these tissues. Hematopoietic stem cells also alter phenotype with cell cycle transit or circadian phase. During a cytokine stimulated cell cycle transit, reversible alterations of differentiation and engraftment occur. Primitive hematopoietic stem cells express a wide variety of adhesion and cytokine receptors and respond quickly with migration and podia extensions on exposure to cytokines. These data suggest an "Open Chromatin" model of stem cell regulation in which there is a fluctuating continuum in the stem cell/progenitor cell compartments, rather than a hierarchical relationship. These observations, along with progress in using low dose treatments and tolerization approaches, suggest many new therapeutic strategies involving stem cells and the creation of a new medical specialty; stemology.


Subject(s)
Hematopoietic Stem Cells/cytology , Animals , Cell Separation , Chimera , Chromatin/genetics , Female , Gene Expression , Hematopoiesis , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/physiology , Humans , Male , Mice , Mice, Congenic , Mice, Inbred BALB C , Mice, Inbred C57BL , Models, Biological , Neoplasms/therapy , Transplantation, Homologous , Transplantation, Isogeneic
9.
J Hematother Stem Cell Res ; 11(6): 913-22, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12590706

ABSTRACT

This study was designed to establish a direct homing assay using purified lineage-negative Sca-1-positive (Lin(-) Sca(+)) murine bone marrow cells and to evaluate the effects of cytokines on homing. C57BL/6 Lin(-) Sca(+) marrow stem cells were labeled with 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) and then injected by tail vein into untreated C57BL/6 mice. Marrow was harvested at various times after cell infusion and analyzed on a high-speed MoFlo cell sorter for fluorescent positive events, using a large event analysis, with at least 16 million total events analyzed. We have shown that homing of Lin(-) Sca(+) cells plateaus by 1 h, and at 3 h post-infusion is linear between 50,000 and 1,000,000 infused cells. This forms a base for a homing assay in which 250,000 CFDA-SE labeled Lin(-) Sca(+) marrow cells are infused and then recovered from marrow 3 h later, followed by a large-event fluorescence-activated cell sorting (FACS) analysis. We found that 7.45-9.32% of infused cells homed and that homing of stem cells cultured for 48 h in interleukin-3 (IL-3), IL-6, IL-11, and steel factor cultured cells was defective when compared to noncultured cells. Exposure of marrow stem cells to IL-3, IL-6, IL-11, and steel factor induces a stem cell homing defect, which probably underlies the engraftment defect previously characterized under these conditions.


Subject(s)
Bone Marrow Transplantation/methods , Cell Movement/drug effects , Cytokines/pharmacology , Hematopoietic Stem Cells/cytology , Animals , Antigens, Differentiation/analysis , Bone Marrow Cells/cytology , Cell Culture Techniques/methods , Graft Survival , Interleukin-11/pharmacology , Interleukin-3/pharmacology , Interleukin-6/pharmacology , Kinetics , Male , Mice , Mice, Inbred C57BL , Spleen/cytology , Stem Cell Factor/pharmacology , Thymus Gland/cytology
10.
In Vitro Cell Dev Biol Anim ; 38(6): 343-51, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12513122

ABSTRACT

Space flight with associated microgravity is complicated by "astronaut's anemia" and other hematologic abnormalities. Altered erythroid differentiation, red cell survival, plasma volume, and progenitor numbers have been reported. We studied the impact of microgravity on engraftable stem cells, culturing marrow cells in rotary wall vessel (RWV) culture chambers mimicking microgravity and in normal gravity nonadherent Teflon bottles. A quantitative competitive engraftment technique was assessed under both conditions in lethally irradiated hosts. We assessed 8-wk engraftable stem cells over a period spanning at least one cell cycle for cytokine (FLT-3 ligand, thrombopoietin [TPO], steel factor)-activated marrow stem cells. Engraftable stem cells were supported out to 56 h under microgravity conditions, and this support was superior to that seen in normal-gravity Teflon bottle cultures out to 40 h, with Teflon bottle culture support superior to RWV from 40 to 56 h. A nadir of stem cell number was seen at 40 h in Teflon and 48 h in RWV, suggesting altered marrow stem cell cycle kinetics under microgravity. This is the first study of engraftable stem cells under microgravity conditions, and the differences between microgravity and normal gravity cultures may present opportunities for unique future stem cell expansion strategies.


Subject(s)
Cell Culture Techniques/methods , Cell Cycle/physiology , Cell Differentiation/physiology , Stem Cells/drug effects , Weightlessness Simulation , Animals , Bioreactors , Bone Marrow Cells , Bone Marrow Transplantation , Cell Culture Techniques/instrumentation , Cell Division/physiology , Graft Survival , Kinetics , Mice , Mice, Inbred BALB C , Rotation , Stem Cells/cytology , Stem Cells/radiation effects
SELECTION OF CITATIONS
SEARCH DETAIL
...